The Atlantic -- The New York Times has a pretty gripping series about the quest to develop a targeted drug for certain forms of metastatic melanoma. As of the second installment we’re at a cliffhanger (spoiler alert): the new drug is producing almost magical shrinkage of tumors. But one patient has died from cancer that crossed the blood-brain barrier -- which the new drug cannot penetrate. Will the other patients in the early stage trial also succumb? How long will the remissions last?
